SKPD / SK Bio - LARVOL DELTA

SK biopharmaceuticals’ Parkinson’s drug restores movement, clears toxic protein in early study (Korea Biomedical Review) - "In preclinical models of GBA1-linked Parkinson’s disease, a genetic subset accounting for up to 15 percent of cases of the disease, SK biopharmaceuticals’ oral candidate SKPD restored motor function and maintained its effect for up to three months after treatment ended, the company reported last week....SK biopharmaceuticals said SKPD reduced alpha-synuclein levels in multiple animal models and also activated lysosomal and autophagy pathways, the brain’s internal systems for clearing damaged proteins and cellular debris."

Preclinical • Parkinson's Disease